Anixa Biosciences (ANIX) Total Current Liabilities (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Total Current Liabilities came in at $1.5 million in Q2 2026, down 20.46% YoY from $1.9 million in Q2 2025, and down 23.69% on a QoQ basis from $2.0 million in Q4 2025.
Anixa Biosciences (ANIX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Total Current Liabilities data on file, last reported at $1.5 million in Q2 2026.
- Quarterly Total Current Liabilities fell 20.46% year-over-year to $1.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.5 million (down 20.46% YoY) and the FY2025 annual result came in at $2.0 million, down 21.32% from the prior year.
- Total Current Liabilities eased to $1.5 million in Q2 2026, from $2.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.5 million in Q4 2024 to a low of $1.2 million in Q2 2022.
- A 5-year average of $1.8 million and a median of $1.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 60.39% — and 2023, when it tumbled 31.06%.
- Tracing ANIX's Total Current Liabilities over 5 years: stood at $2.0 million in 2022, then slipped by 0.44% to $2.0 million in 2023, then advanced by 23.27% to $2.5 million in 2024, then slipped by 21.32% to $2.0 million in 2025, then fell by 23.69% to $1.5 million in 2026.
- The last three Total Current Liabilities figures came in at $1.5 million (Q2 2026), $2.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Anixa Biosciences | 122.95 Mn | 122.95 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.50 Mn |
| Oct 31, 2025 | 1.97 Mn |
| Jul 31, 2025 | 2.07 Mn |
| Apr 30, 2025 | 1.89 Mn |
| Jan 31, 2025 | 2.00 Mn |
| Oct 31, 2024 | 2.50 Mn |
| Jul 31, 2024 | 2.00 Mn |
| Apr 30, 2024 | 1.68 Mn |
| Jan 31, 2024 | 1.66 Mn |
| Oct 31, 2023 | 2.03 Mn |
| Jul 31, 2023 | 1.86 Mn |
| Apr 30, 2023 | 1.54 Mn |
| Jan 31, 2023 | 1.23 Mn |
| Oct 31, 2022 | 2.04 Mn |
| Jul 31, 2022 | 1.47 Mn |
| Apr 30, 2022 | 1.19 Mn |
| Jan 31, 2022 | 1.79 Mn |
| Oct 31, 2021 | 1.27 Mn |
| Jul 31, 2021 | 1.21 Mn |
| Apr 30, 2021 | 1.44 Mn |